Are you up-to-date on the newest treatments for patients with advanced melanoma, the deadliest of skin cancers? Antoni Ribas and Grace Cherry will share promising medical breakthroughs in melanoma research, uncovering its biology, what makes it grow, and how it interacts with the immune system. You’ll hear about new therapies that are based on blocking the oncogene BRAF with novel BRAF and MEK inhibitors, and that unleash an antitumor immune response by blocking negative immune regulators like CTLA4 and PD-1. Learn how these novel agents differ from standard chemotherapy treatments in their mechanisms of action, toxicity profiles, and side effects, and what the nursing implications are.

**Content Area:** Clinical Practice

**Content Level:** Advanced

**Speaker:**
Grace Cherry, RN, MSN
Melanoma Nurse Practitioner
UCLA Oncology Clinic
Santa Monica, CA
gcherry@mednet.ucla.edu

**Full Disclosure:**
Nothing to Disclose

**Speaker:**
Antoni Ribas, MD, PhD
Professor of Medicine, Surgery, and Molecular and Medical Pharmacology
University of California, Los Angeles

**Full Disclosure:**
Nothing to Disclose

**Objectives:**
At the end of this session, participants will be able to:
1. Describe the different adverse effects of immunotherapy, BRAF inhibitors, and MEK inhibitors.
2. Explain management interventions for adverse effects.